MAS825: meta-analysis of COVID-19 studies

All studies   Mortality   Serious outcomes   Recovery   RCTs   RCT mortality   Peer-reviewed   All outcomes  
Meta-analysis1 study · 138 patientsc19early.org

MAS825 for COVID-19

Serious outcome risk
MAS825
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−16%
Mortality (1)−16%
RCTs (1)−16%
Late (1)−16%
00.511.5+
← MAS825
reduces riskIncreased
risk →
c19early.org
October 2026

MAS825 COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Hakim (DB RCT)−16%1.16 · 0.74–1.83death26/6823/70MAS-COVID
Late treatment−16%1.16 · 0.74–1.8326/6823/7016% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.52
All studies−16%1.16 · 0.74–1.8326/6823/7016% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5200.511.52+
Rotate screen for more detailsIncrease width for more details
← MAS825
reduces riskMAS825
increases risk →
c19early.org
October 2026

MAS825 COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Hakim (DB RCT)−16%1.16 · 0.74–1.8326/6823/70MAS-COVID
Late treatment−16%1.16 · 0.74–1.8326/6823/7016% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.52
All studies−16%1.16 · 0.74–1.8326/6823/7016% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5200.511.52+
Rotate screen for more detailsIncrease width for more details
← MAS825
reduces riskMAS825
increases risk →
c19early.org
October 2026

MAS825 COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Hakim (DB RCT)−16%1.16 · 0.74–1.83death26/6823/70MAS-COVID
Late treatment−16%1.16 · 0.74–1.8326/6823/7016% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.52
All studies−16%1.16 · 0.74–1.8326/6823/7016% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5200.511.52+
Rotate screen for more detailsIncrease width for more details
← MAS825
reduces riskMAS825
increases risk →
c19early.org
October 2026

MAS825 COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Hakim (DB RCT)−7%1.07 · 0.76–1.52no recov.68 (n)70 (n)MAS-COVID
Late treatment−7%1.07 · 0.76–1.5268 (n)70 (n)7% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.7
All studies−7%1.07 · 0.76–1.5268 (n)70 (n)7% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.700.511.52+
Rotate screen for more detailsIncrease width for more details
← MAS825
reduces riskMAS825
increases risk →
c19early.org
October 2026

MAS825 COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Hakim (DB RCT)−16%1.16 · 0.74–1.83death26/6823/70MAS-COVID
Late treatment−16%1.16 · 0.74–1.8326/6823/7016% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.52
All studies−16%1.16 · 0.74–1.8326/6823/7016% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5200.511.52+
Rotate screen for more detailsIncrease width for more details
← MAS825
reduces riskMAS825
increases risk →
c19early.org
October 2026

MAS825 COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Hakim (DB RCT)−16%1.16 · 0.74–1.8326/6823/70MAS-COVID
Late treatment−16%1.16 · 0.74–1.8326/6823/7016% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.52
All studies−16%1.16 · 0.74–1.8326/6823/7016% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5200.511.52+
Rotate screen for more detailsIncrease width for more details
← MAS825
reduces riskMAS825
increases risk →
c19early.org
October 2026

MAS825 COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Hakim (DB RCT)−16%1.16 · 0.74–1.83death26/6823/70MAS-COVID
Late treatment−16%1.16 · 0.74–1.8326/6823/7016% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.52
All studies−16%1.16 · 0.74–1.8326/6823/7016% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5200.511.52+
Rotate screen for more detailsIncrease width for more details
← MAS825
reduces riskMAS825
increases risk →